Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

AMIODARONE HCL

8 general benefit · 1 not a benefit

Other products in the same Health Canada class (C01B) — coverage varies; not interchangeable

  • Disopyramide (Norpace): general benefit, Not a benefit, Listing status unconfirmed
  • Flecainide (Tambocor): general benefit, Not a benefit
  • Mexiletine (Mexitil): general benefit, Not a benefit
  • Propafenone (Rythmol): general benefit

Amiodarone · DIN 02364336 · 200mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Amiodarone · DIN 02364336 Manufacturer: Sanis Health Inc.; listing date 2011-10-25 Health Canada: Marketed since 2026-05-26 · brand AMIODARONE · ATC C01BD01 AMIODARONE · form Tablet · route Oral · ingredients AMIODARONE HYDROCHLORIDE 200 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Amiodarone: Formulary list price $0.3706/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3706 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84924 · Verify on the e-Formulary ↗ (DIN 02364336)

Source record
DIN 02364336: Amiodarone Raw flags: chronicUseMed=Y, sec3=Y Item: 240400072; group id 273; item number 0565; lccId None; manufacturer id SAI Source form: Tab; strength: 200mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3706; ministry $0.3706 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02364336 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84924 Therapeutic Notes (formulary) The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.
Interchangeable products
Amiodarone · DIN 02385465 · $0.3706 Apo-Amiodarone · DIN 02246194 · $0.3706 Cordarone · DIN 02036282 · not recorded Jamp Amiodarone · DIN 02531844 · $0.3706 PMS-Amiodarone · DIN 02242472 · $0.3706 Riva-Amiodarone · DIN 02247217 · $0.3706 Sandoz Amiodarone · DIN 02243836 · $0.3706 Teva-Amiodarone · DIN 02239835 · $0.3706
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02364336
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Amiodarone · DIN 02385465 · 200mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Amiodarone · DIN 02385465 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2012-06-10 · brand AMIODARONE · ATC C01BD01 AMIODARONE · form Tablet · route Oral · ingredients AMIODARONE HYDROCHLORIDE 200 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Amiodarone: Formulary list price $0.3706/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3706 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87109 · Verify on the e-Formulary ↗ (DIN 02385465)

Source record
DIN 02385465: Amiodarone Raw flags: chronicUseMed=Y, sec3=Y Item: 240400072; group id 273; item number 0565; lccId None; manufacturer id SIV Source form: Tab; strength: 200mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3706; ministry $0.3706 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385465 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87109 Therapeutic Notes (formulary) The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.
Interchangeable products
Amiodarone · DIN 02364336 · $0.3706 Apo-Amiodarone · DIN 02246194 · $0.3706 Cordarone · DIN 02036282 · not recorded Jamp Amiodarone · DIN 02531844 · $0.3706 PMS-Amiodarone · DIN 02242472 · $0.3706 Riva-Amiodarone · DIN 02247217 · $0.3706 Sandoz Amiodarone · DIN 02243836 · $0.3706 Teva-Amiodarone · DIN 02239835 · $0.3706
Shortage status: resolved shortage (ended 2020-12-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02385465
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Amiodarone · DIN 02246194 · 200mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Amiodarone · DIN 02246194 Manufacturer: Apotex Inc.; listing date 2004-04-06 Health Canada: Marketed since 2003-09-05 · brand APO-AMIODARONE TABLETS · ATC C01BD01 AMIODARONE · form Tablet · route Oral · ingredients AMIODARONE HYDROCHLORIDE 200 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Amiodarone: Formulary list price $0.3706/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3706 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70344 · Verify on the e-Formulary ↗ (DIN 02246194)

Source record
DIN 02246194: Apo-Amiodarone Raw flags: chronicUseMed=Y, sec3=Y Item: 240400072; group id 273; item number 0565; lccId None; manufacturer id APX Source form: Tab; strength: 200mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3706; ministry $0.3706 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246194 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70344 Therapeutic Notes (formulary) The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.
Interchangeable products
Amiodarone · DIN 02364336 · $0.3706 Amiodarone · DIN 02385465 · $0.3706 Cordarone · DIN 02036282 · not recorded Jamp Amiodarone · DIN 02531844 · $0.3706 PMS-Amiodarone · DIN 02242472 · $0.3706 Riva-Amiodarone · DIN 02247217 · $0.3706 Sandoz Amiodarone · DIN 02243836 · $0.3706 Teva-Amiodarone · DIN 02239835 · $0.3706
Shortage status: resolved shortage (ended 2024-06-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246194
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Amiodarone · DIN 02531844 · 200mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Amiodarone · DIN 02531844 Manufacturer: Jamp Pharma Corporation; listing date 2023-05-31 Health Canada: Marketed since 2023-04-12 · brand JAMP AMIODARONE · ATC C01BD01 AMIODARONE · form Tablet · route Oral · ingredients AMIODARONE HYDROCHLORIDE 200 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Amiodarone: Formulary list price $0.3706/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3706 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102093 · Verify on the e-Formulary ↗ (DIN 02531844)

Source record
DIN 02531844: Jamp Amiodarone Raw flags: chronicUseMed=Y, sec3=Y Item: 240400072; group id 273; item number 0565; lccId None; manufacturer id JPC Source form: Tab; strength: 200mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3706; ministry $0.3706 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02531844 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102093
Interchangeable products
Amiodarone · DIN 02364336 · $0.3706 Amiodarone · DIN 02385465 · $0.3706 Apo-Amiodarone · DIN 02246194 · $0.3706 Cordarone · DIN 02036282 · not recorded PMS-Amiodarone · DIN 02242472 · $0.3706 Riva-Amiodarone · DIN 02247217 · $0.3706 Sandoz Amiodarone · DIN 02243836 · $0.3706 Teva-Amiodarone · DIN 02239835 · $0.3706
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02531844
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Amiodarone · DIN 02242472 · 200mg · tablet

General benefitMarketed · checked 2026-09-18
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Amiodarone · DIN 02242472 Manufacturer: Pharmascience Inc.; listing date 2001-06-07 Health Canada: Marketed since 2000-07-28 · brand PMS-AMIODARONE · ATC C01BD01 AMIODARONE · form Tablet · route Oral · ingredients AMIODARONE HYDROCHLORIDE 200 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Amiodarone: Formulary list price $0.3706/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3706 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66199 · Verify on the e-Formulary ↗ (DIN 02242472)

Source record
DIN 02242472: PMS-Amiodarone Raw flags: chronicUseMed=Y, sec3=Y Item: 240400072; group id 273; item number 0565; lccId None; manufacturer id PMS Source form: Tab; strength: 200mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3706; ministry $0.3706 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242472 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66199 Therapeutic Notes (formulary) The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.
Interchangeable products
Amiodarone · DIN 02364336 · $0.3706 Amiodarone · DIN 02385465 · $0.3706 Apo-Amiodarone · DIN 02246194 · $0.3706 Cordarone · DIN 02036282 · not recorded Jamp Amiodarone · DIN 02531844 · $0.3706 Riva-Amiodarone · DIN 02247217 · $0.3706 Sandoz Amiodarone · DIN 02243836 · $0.3706 Teva-Amiodarone · DIN 02239835 · $0.3706
Shortage status: active shortage (reported 2026-09-03, estimated to end 2026-09-15, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242472
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Riva-Amiodarone · DIN 02247217 · 200mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Riva-Amiodarone · DIN 02247217 Manufacturer: Laboratoire Riva Inc.; listing date 2021-08-31 Health Canada: Marketed since 2024-11-07 · brand RIVA-AMIODARONE · ATC C01BD01 AMIODARONE · form Tablet · route Oral · ingredients AMIODARONE HYDROCHLORIDE 200 MG · company Laboratoire riva inc. · schedule Prescription
Check this DIN again · Health Canada product record

Riva-Amiodarone: Formulary list price $0.3706/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3706 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71459 · Verify on the e-Formulary ↗ (DIN 02247217)

Source record
DIN 02247217: Riva-Amiodarone Raw flags: chronicUseMed=Y, sec3=Y Item: 240400072; group id 273; item number 0565; lccId None; manufacturer id RIA Source form: Tab; strength: 200mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3706; ministry $0.3706 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247217 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71459
Interchangeable products
Amiodarone · DIN 02364336 · $0.3706 Amiodarone · DIN 02385465 · $0.3706 Apo-Amiodarone · DIN 02246194 · $0.3706 Cordarone · DIN 02036282 · not recorded Jamp Amiodarone · DIN 02531844 · $0.3706 PMS-Amiodarone · DIN 02242472 · $0.3706 Sandoz Amiodarone · DIN 02243836 · $0.3706 Teva-Amiodarone · DIN 02239835 · $0.3706
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247217
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Amiodarone · DIN 02243836 · 200mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Amiodarone · DIN 02243836 Manufacturer: Sandoz Canada Inc.; listing date 2002-07-29 Health Canada: Marketed since 2005-12-02 · brand SANDOZ AMIODARONE · ATC C01BD01 AMIODARONE · form Tablet · route Oral · ingredients AMIODARONE HYDROCHLORIDE 200 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Amiodarone: Formulary list price $0.3706/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3706 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67777 · Verify on the e-Formulary ↗ (DIN 02243836)

Source record
DIN 02243836: Sandoz Amiodarone Raw flags: chronicUseMed=Y, sec3=Y Item: 240400072; group id 273; item number 0565; lccId None; manufacturer id SDZ Source form: Tab; strength: 200mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3706; ministry $0.3706 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243836 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67777 Therapeutic Notes (formulary) The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.
Interchangeable products
Amiodarone · DIN 02364336 · $0.3706 Amiodarone · DIN 02385465 · $0.3706 Apo-Amiodarone · DIN 02246194 · $0.3706 Cordarone · DIN 02036282 · not recorded Jamp Amiodarone · DIN 02531844 · $0.3706 PMS-Amiodarone · DIN 02242472 · $0.3706 Riva-Amiodarone · DIN 02247217 · $0.3706 Teva-Amiodarone · DIN 02239835 · $0.3706
Shortage status: resolved shortage (ended 2024-06-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243836
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Amiodarone · DIN 02239835 · 200mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Amiodarone · DIN 02239835 Manufacturer: Teva Canada Limited; listing date 1999-09-15 Health Canada: Marketed since 2010-06-02 · brand TEVA-AMIODARONE · ATC C01BD01 AMIODARONE · form Tablet · route Oral · ingredients AMIODARONE HYDROCHLORIDE 200 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Amiodarone: Formulary list price $0.3706/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3706 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63322 · Verify on the e-Formulary ↗ (DIN 02239835)

Source record
DIN 02239835: Teva-Amiodarone Raw flags: chronicUseMed=Y, sec3=Y Item: 240400072; group id 273; item number 0565; lccId None; manufacturer id TEV Source form: Tab; strength: 200mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3706; ministry $0.3706 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239835 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63322 Therapeutic Notes (formulary) The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.
Interchangeable products
Amiodarone · DIN 02364336 · $0.3706 Amiodarone · DIN 02385465 · $0.3706 Apo-Amiodarone · DIN 02246194 · $0.3706 Cordarone · DIN 02036282 · not recorded Jamp Amiodarone · DIN 02531844 · $0.3706 PMS-Amiodarone · DIN 02242472 · $0.3706 Riva-Amiodarone · DIN 02247217 · $0.3706 Sandoz Amiodarone · DIN 02243836 · $0.3706
Shortage status: resolved shortage (ended 2025-10-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239835
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cordarone · DIN 02036282 · 200mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2016-07-12 — choose a marketed DIN from the same-category list.Discontinued 2016-07-12 · checked 2026-09-18
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2016-07-12 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2016-07-12 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cordarone · DIN 02036282 Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2016-07-12 · brand CORDARONE · ATC C01BD01 AMIODARONE · form Tablet · route Oral · ingredients AMIODARONE HYDROCHLORIDE 200 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Cordarone: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15489 · Verify on the e-Formulary ↗ (DIN 02036282)

Source record
DIN 02036282: Cordarone Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240400072; group id 273; item number 0565; lccId None; manufacturer id PFI Source form: Tab; strength: 200mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02036282 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15489 Therapeutic Notes (formulary) The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.
Interchangeable products
Amiodarone · DIN 02364336 · $0.3706 Amiodarone · DIN 02385465 · $0.3706 Apo-Amiodarone · DIN 02246194 · $0.3706 Jamp Amiodarone · DIN 02531844 · $0.3706 PMS-Amiodarone · DIN 02242472 · $0.3706 Riva-Amiodarone · DIN 02247217 · $0.3706 Sandoz Amiodarone · DIN 02243836 · $0.3706 Teva-Amiodarone · DIN 02239835 · $0.3706
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02036282
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2016-07-12 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:04 Cardiac Drugs

DISOPYRAMIDE

· 3 products · Listed, not a benefit (1), General benefit (1), Temporary benefit (1) · strengths: 100mg · Cap

FLECAINIDE ACETATE

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 50mg, 100mg · Tab

MEXILETINE HCL

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 100mg, 200mg · Cap

PROPAFENONE HCL

· 6 products · General benefit · strengths: 150mg, 300mg · Tab

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

AMLODIPINE

· 56 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

DIGOXIN

· 7 products · General benefit · strengths: 0.05mg/mL, 0.0625mg, 0.125mg · O/L, Tab

DILTIAZEM HCL

· 93 products · General benefit (91), Listed, not a benefit (2) · strengths: 120mg, 180mg, 240mg, 300mg, 360mg, 30mg, 60mg · ER Tab, LA Cap, SR Cap, Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04 and 9 more
Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications Considering its potential for life-threatening side effects and the substantial management difficulties associated with its oral use, TEVA-AMIODARONE (amiodarone hydrochloride) is indicated only for the treatment of patients with the following documented life-threatening, recurrent ventricular arrhythmias when these have not responded to documented adequate doses of other available antiarrhythmics, or when alternative agents could not be tolerated: • Hemodynamically unstable ventricular tachycardia (VT). • Recurrent ventricular fibrillation (VF). As is the case for other antiarrhythmic agents, there is no evidence from controlled clinical trials that the use of amiodarone hydrochloride tablets favourably affects survival. Because the life-threatening nature of arrhythmias treated, potential interaction with prior therapy, and potential exacerbation of arrhythmia, initiation of therapy with TEVA- AMIODARONE should be carried out in the hospital. TEVA-AMIODARONE should be used only by healthcare professionals familiar with and with access to (directly or referral) the use of all available modalities for treating recurrent life- threatening ventricular ar… https://pdf.hres.ca/dpd_pm/00084740.PDF PM date: 2026-05-13 Source product: TEVA-AMIODARONE; DIN 02239835; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

PMS-Amiodarone · DIN 02242472 Shortage status: active shortage (reported 2026-09-03, estimated to end 2026-09-15, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242472

Check this DIN again

Other review policies

For Cordarone: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026